Government whistleblower programs incentivize whistleblowers by rewarding successful whistleblowers with a percentage of the money that the government recovers as a result of the whistleblower’s information. KTMC’s whistleblower team knows how to fight for whistleblower awards and position clients in order to advocate for the top of the award range.
Our whistleblower team has successfully obtained significant awards from the SEC pursuant to the SEC’s anonymous whistleblower program and from DOJ in both intervened and litigated qui tam cases. These public qui tam cases include:
- Bayer Pharmaceutical litigation - $46 million dollar settlement, with 28.5% share to whistleblower.
- Biotek ReMEDys - $20 million settlement with a 20% relator’s share
- Pentec Health - $17 million settlement with 22% relator’s share
- Doshi Diagnostics – $15.5 settlement with 18% relator’s share on federal and state claims in three separate whistleblower cases, including a case brought by KTMC
- SNAP Diagnostics - $3.925 million with a 23% relator’s share
Whistleblower awards depend on many factors, including the quality and utility of the information provided by the whistleblower and the work performed by the whistleblower’s attorneys in support of the government’s investigation. KTMC’s whistleblower team, which includes attorneys with deep securities law expertise and former federal prosecutors, knows how to advocate for whistleblower awards and seek maximum recoveries.
If you would like to speak to a member of our whistleblower group about a potential whistleblower matter, please contact us to schedule a case evaluation. All case evaluations are confidential and free.